Hongxia Jiang | Health Sciences | Best Researcher Award

Posted on by sciencefather

Dr. Hongxia Jiang | Health Sciences | Best Researcher Award 

Dr. Hongxia Jiang, Zhongnan hospital of Wuhan University, China

Dr. Hongxia Jiang is a distinguished medical professional at Zhongnan Hospital of Wuhan University, China, renowned for her expertise in clinical research and patient-centered care. With a strong background in health sciences and a commitment to advancing medical innovation, Dr. Jiang has contributed significantly to evidence-based medical practices through both her clinical work and research endeavors. Her dedication to improving healthcare outcomes and her role in advancing translational medicine make her a respected figure in the Chinese medical community and beyond.

Profile

Scopus

🎓 Early Academic Pursuits

Dr. Hongxia Jiang began her academic journey with a passion for science and a dedication to improving human health. She pursued her medical education at one of China’s esteemed institutions, demonstrating excellence in both academic knowledge and clinical training. Her early focus was on internal medicine and translational healthcare—fields where she showed an affinity for integrating diagnostics, treatment, and research.

From her undergraduate years, Dr. Jiang stood out for her analytical mindset and problem-solving ability, frequently contributing to peer-reviewed student research journals and clinical practice groups. Her academic mentors recognized her early potential, encouraging her to pursue a path that blends clinical service with cutting-edge research—a combination that has remained at the heart of her career.

🩺 Professional Endeavors

Currently serving at Zhongnan Hospital of Wuhan University, a top-tier teaching and research hospital in China, Dr. Jiang plays a vital role in both clinical operations and medical research. Her clinical acumen, especially in managing complex cases, has earned her trust among patients and peers alike.

As a dedicated physician, she specializes in comprehensive patient care, focusing on diagnostics, preventive medicine, and therapeutic innovation. She is also actively involved in mentoring younger medical staff, shaping the next generation of clinicians with a strong emphasis on ethical practice and evidence-based treatment.

Moreover, Dr. Jiang has been a key contributor to several interdisciplinary medical initiatives at the hospital, particularly in collaboration with departments like oncology, infectious disease, and intensive care. These efforts have not only improved patient outcomes but also paved the way for protocol innovations adopted at other institutions.

🔬 Contributions and Research Focus

Dr. Jiang’s research spans multiple areas within clinical and translational medicine, with special interests in:

  • Molecular diagnostics and biomarker discovery

  • Infectious disease management and public health surveillance

  • Cancer therapy optimization and drug resistance mechanisms

  • Clinical trials focused on novel treatment approaches

She has published in respected national and international medical journals and has presented her findings at conferences and medical symposia across Asia and Europe. Her research work bridges the gap between laboratory science and bedside application, ensuring that scientific innovation directly benefits patients.

Dr. Jiang is also known for pioneering collaborative projects, often engaging with multi-disciplinary teams across China and abroad. This has led to co-authored publications and joint research funding awards that support ongoing medical advancements.

🏅 Accolades and Recognition

Dr. Hongxia Jiang has received numerous accolades that recognize both her clinical excellence and research contributions. These include:

  • Outstanding Physician Award by Zhongnan Hospital

  • Best Paper Presentation at a national medical research forum

  • Research Grant Recipient for translational medicine from a provincial science foundation

  • Repeated acknowledgments from patients and hospital leadership for her empathy, innovation, and leadership

Her consistent contributions have made her a role model in the Chinese healthcare system, and she is frequently invited as a guest lecturer and expert panelist on public health and hospital quality initiatives.

🌍 Impact and Influence

Dr. Jiang’s work has had a profound impact not only on her institution but also on regional health policies and treatment protocols. Her research on infection control and clinical interventions during public health crises (including during the COVID-19 pandemic) has been cited in shaping response strategies in Wuhan and neighboring provinces.

She is a respected collaborator and continues to influence public health discourse, advocating for data-driven care, equitable access to healthcare, and patient safety.

🌟 Legacy and Future Contributions

Looking ahead, Dr. Jiang is committed to advancing global health through collaborative science, with aspirations to lead international trials and establish regional centers of research excellence. Her vision includes:

  • Creating more patient-centered care models

  • Integrating AI and machine learning into diagnostics

  • Championing women in medicine and research leadership

Her legacy is being built not just through research papers or clinical breakthroughs but through the lives she transforms and the systems she helps innovate for future generations.

📝Publication Top Notes

A cross-sectional study on nutritional risk and frailty in elderly patients with chronic obstructive pulmonary disease

Author: L., Liu, Lingfang, Y., Fang, Yanhong, J., Dong, Jia, … Z., Cheng, Zhenshun, C., Wu, Changrong

Journal: Medical Journal of Wuhan University

Year: 2024

 

 

Cheng Ni | Health Sciences | Best Researcher Award | 13442

Posted on by sciencefather

Prof. Cheng Ni | Health Sciences | Best Researcher Award

Prof. Cheng Ni, Cancer Hospital, Chinese Academy of Medical Sciences, China

Prof. Cheng Ni, M.D., Ph.D. is a Professor and Consultant Anesthesiologist at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, where he also serves as Associate Chief of the Department of Anesthesiology. With extensive clinical and academic experience in thoracic anesthesiology, perioperative neuroprotection, and cancer pain management, Prof. Ni has held key roles at leading institutions including Peking University and Harvard University. His research focuses on perioperative neurocognitive disorders, tumor immunology, and the application of AI in anesthesiology. He has published over 50 SCI-indexed articles and holds 11 authorized patents.

Profile

Scopus

🎓 Early Academic Pursuits

Prof. Cheng Ni’s academic journey is a testament to dedication and intellectual rigor. He began his medical education at Capital Medical University, earning his M.D. in 2003 and M.S. in 2005, laying a solid foundation in medical sciences. His passion for deeper understanding and specialization led him to pursue a Ph.D. at Peking University, one of China’s most prestigious institutions, which he completed in 2012. This advanced academic training equipped him with a rich knowledge base in anesthesiology and related biomedical sciences, paving the way for a distinguished career in clinical practice, teaching, and research.

🩺 Professional Endeavors

Prof. Ni’s professional career reflects a steady and impactful rise through China’s top-tier medical institutions. He began as a Resident at Peking University Third Hospital (2005–2008) and subsequently served as an Attending Anesthesiologist (2008–2015). During this period, he gained hands-on clinical experience and honed his leadership abilities.

In 2013–2014, he expanded his global perspective as a Postdoctoral Research Fellow at Harvard University, engaging with cutting-edge international research. Upon his return, he held several key administrative and academic roles at Peking University, including Chief Secretary of the Faculty of Anesthesiology, and Associate Consultant and Associate Professor.

In 2020, Prof. Ni joined the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, a top national institution, as a Consultant and Associate Professor. His expertise quickly earned him leadership roles as Associate Chief of the Department of Anesthesiology, and by 2021, he was promoted to Professor and Consultant. He also became a Ph.D. Supervisor in 2023, mentoring the next generation of clinical researchers and specialists.

🔬 Contributions and Research Focus

Prof. Ni’s research contributions span multiple high-impact areas in modern anesthesiology and cancer care. His primary interests include:

  • Perioperative neurocognitive disorders 🧠

  • Thoracic anesthesiology and neuroprotection 💨🛡️

  • Cancer pain management 🧬

  • Genetics and tumor immunology 🧫

  • AI in anesthesiology research 🤖🩺

He has authored over 50 peer-reviewed articles in leading SCI-indexed journals, including Aging Cell, CNS Neuroscience & Therapeutics, Life Sciences, and Anesthesia & Analgesia. His recent publications explore the neuroinflammatory response during surgery, the effects of anesthesia on brain aging, and the integration of hybrid learning models for brain cell identification—blending medical science with artificial intelligence.

In addition to journal publications, Prof. Ni has contributed to 12 academic monographs and holds 11 authorized patents, underscoring his commitment to translational research and innovation.

🏅 Accolades and Recognition

Prof. Cheng Ni is widely respected in China’s medical and academic communities. His achievements have been recognized through his appointment to senior roles such as:

  • Chief Secretary of Anesthesiology Faculty, Peking University Health Science Center

  • Associate Chief of the Department of Anesthesiology at China’s National Cancer Center

  • Ph.D. Supervisor, guiding graduate-level research and fostering academic excellence

These appointments are not only acknowledgments of his skill and dedication but also affirmations of his influence in shaping anesthesiology and cancer care practices in China.

🌍 Impact and Influence

Prof. Ni’s work resonates far beyond the operating room. His integration of AI into anesthesiology research marks a forward-thinking approach to modern medicine. By exploring the cognitive effects of anesthesia, he contributes to improving surgical outcomes and patient safety, particularly in aging populations.

His leadership and mentorship roles at premier institutions like Peking University and the Cancer Hospital, CAMS, have helped nurture a generation of professionals equipped with both technical excellence and ethical insight.

Furthermore, his international collaboration with Harvard University has brought valuable cross-cultural research experience into Chinese clinical research settings, promoting a global standard in anesthesiology and perioperative medicine.

🌱 Legacy and Future Contributions

Looking ahead, Prof. Ni is poised to play a pivotal role in shaping the future of anesthesiology in cancer care. His continued emphasis on neuroprotection, chronic pain management, and artificial intelligence applications signals a progressive vision aligned with global health priorities.

As a Ph.D. supervisor and seasoned educator, his mentorship will continue to inspire emerging scholars. His innovations in clinical protocols and diagnostic tools will likely set new benchmarks in anesthetic safety and cancer patient recovery.

Prof. Cheng Ni stands as a bridge between tradition and innovation, combining deep clinical knowledge with research excellence to lead transformative change in anesthesiology and oncology care.

Publication Top Notes

Aged hippocampal single-cell atlas screening unveils disrupted neuroglial system in postoperative cognitive impairment

Author: Z., Suo, Zizheng, T., Xiao, Ting, Y., Qu, Yinyin, … H., Zheng, Hui, C., Ni, Cheng
Journal: Aging Cell
Year: 2025

Year: 2024

 

Matheus Sewastjanow-Silva | Health Sciences | Best Researcher Award

Posted on by sciencefather

Dr. Matheus Sewastjanow-Silva | Health Sciences | Best Researcher Award

Research investigator at The University of Texas MD Anderson Cancer Center, United States

Matheus Sewastjanow da Silva is a Research Investigator at the University of Texas MD Anderson Cancer Center, focusing on clinical studies databases and manuscript analysis. Previously, he worked in Jaffer Ajani’s lab and was a General Practitioner in Brazil, providing emergency and outpatient care. He holds an M.D. from the Federal University of Minas Gerais (UFMG), with internships in various medical specialties at institutions like A.C. Camargo Cancer Center and Jackson Memorial Hospital. Matheus has extensive research experience in surgery and immunology and has actively participated in volunteer medical campaigns and student leadership roles.

Professional Profiles:

🎓 Education

Matheus Sewastjanow da Silva, M.D., earned his Doctor of Medicine (M.D.) from the Federal University of Minas Gerais School of Medicine in Brazil (2012-2018). His education included additional internships at prominent institutions. He completed a rural outpatient care internship in Esmeraldas, Brazil, and specialized training in Otolaryngology – Head & Neck Surgery at A.C. Camargo Cancer Center, São Paulo, and in Skin, Head & Neck, and Micro/Reconstructive Surgery at Barretos Cancer Hospital. Dr. da Silva also trained in Transplant Surgery and Mohs Micrographic Surgery at the University of Miami. His education was supplemented by various courses, including Pediatric Advanced Life Support (PALS), Advanced Cardiovascular Life Support (ACLS), clinical emergencies, and advanced dermatological surgery. Additionally, he completed courses in clinical therapeutics, psychosomatic diseases, primary immunodeficiencies, and languages (French and Latin). This diverse and rigorous training underscores his commitment to comprehensive medical education and patient care.

Professional Experience

Dr. Matheus Sewastjanow da Silva is currently a Research Investigator in Shirley Su’s research group at the Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center (07/2024-present). His responsibilities include managing clinical studies/trials databases, analyzing and writing manuscripts, and utilizing tools such as RedCap, Epic/SlicerDicer, Foundry, Universe, and Prometheus. Previously, he worked as a Research Investigator in Jaffer Ajani’s lab at the Department of Gastrointestinal Medical Oncology at the same institution (09/2020-06/2024), where he handled clinical samples, patient enrollment, and various laboratory techniques. Before his roles at MD Anderson, Dr. da Silva served as a Physician/General Practitioner in multiple clinics and hospitals across Brazil, providing both outpatient and emergency care, including treating COVID-19 patients. His roles included positions at Nazare Public Family Medicine Clinic, Private Hospital Santa Helena, Public Hospital Vinte e Cinco de Maio, and several Public Emergency Care Centers. Additionally, he gained research experience as an Assistant at the Federal University of Minas Gerais, contributing to studies in General Surgery and Biochemistry, Cellular, and Molecular Immunology.

Research Interest

Dr. Matheus Sewastjanow da Silva is deeply interested in clinical and translational research, focusing on head and neck surgery, gastrointestinal oncology, and emergency medicine. His current research in Shirley Su’s group at MD Anderson Cancer Center involves filling and maintaining clinical studies and trials databases, as well as analyzing and writing manuscripts. He has extensive experience with advanced tools like RedCap, Epic/SlicerDicer, Foundry, Universe, and Prometheus. Dr. da Silva’s previous research in Jaffer Ajani’s lab involved the collection and processing of clinical samples, patient enrollment, DNA/RNA extraction, cell culture, and various molecular biology techniques such as qPCR, Western Blotting, and viral transfections. His research interests extend to the development of novel therapeutic strategies, biomarker discovery, and improving patient outcomes in oncology. Additionally, he is passionate about medical education and the integration of research findings into clinical practice to enhance healthcare delivery.

Award and Honors

Dr. Matheus Sewastjanow da Silva has been recognized for his outstanding contributions to medicine and research through numerous awards and honors. His notable achievements include multiple grant awards and scholarships from esteemed organizations such as the National Council for Scientific and Technological Development (CNPq) and the Research Support Foundation of the State of Minas Gerais (FAPEMIG). Throughout his academic and professional journey, Dr. da Silva has demonstrated exceptional commitment and excellence in his field, earning accolades for his research work, particularly in biochemistry, cellular and molecular immunology, and oncology. His dedication to advancing medical knowledge and improving patient care has been consistently acknowledged, solidifying his reputation as a distinguished physician and researcher in the medical community.

Research Experience 🔬

  • Research Assistant at UFMG General Surgery Laboratory – Andy Petroianu M.D., PhD (07/2015 – 12/2017)
    Roles: Research design, patient consenting, data collection/analysis, database management, manuscript preparation.
  • Research Assistant at UFMG Biochemistry, Cellular and Molecular Immunology Laboratory II – Dawidson Assis Gomes, Msc, PhD (10/2012 – 07/2015)
    Grant Awards: CNPq, FAPEMIG
    Roles: Lab preparations, rodent handling, tissue processing, DNA/RNA extraction, immunohistochemistry, PCR, ELISA, Western Blotting, flow cytometry, data analysis, manuscript preparation.

Research Skills

Proficient in managing clinical studies and trials databases using RedCap, Epic/SlicerDicer, Foundry, Universe, and Prometheus, I have extensive experience in collecting, processing, and managing clinical samples, including blood, ascites, and tissue. My molecular techniques expertise encompasses DNA/RNA extraction, qPCR, Western Blotting, viral transfections, and immunohistochemistry. Additionally, I am skilled in cell isolation, culture, and viral transfections. I have significant experience in rodent handling and conducting mouse studies. Competent in statistical analysis and data interpretation using various software tools, I am also proficient in writing and reviewing abstracts, articles, manuscripts, posters, and slide presentations. My laboratory skills include preparing buffers, tissue staining, cryostat tissue sectioning, PCR, ELISA, flow cytometry, and cell culture.

Publications

  • SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel
    • Authors: Yamashita, K., Sewastjanow-Silva, M., Yoshimura, K., …, Wang, L., Ajani, J.A.
    • Year: 2024
  • Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study
    • Authors: Sewastjanow-Silva, M., Xiao, L., Gonzalez, G.N., …, Ajani, J.A., Murphy, M.B.
    • Year: 2024
  • Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target
    • Authors: Rogers, J.E., Yamashita, K., Sewastjanow-Silva, M., …, Waters, R.E., Ajani, J.
    • Year: 2023
    • Citations: 2
  • Challenges and Prospects of Patient-Derived Xenografts for Cancer Research
    • Authors: Jin, J., Yoshimura, K., Sewastjanow-Silva, M., Song, S., Ajani, J.A.
    • Year: 2023
    • Citations: 12
  • Evolution of Immune and Stromal Cell States and Ecotypes during Gastric Adenocarcinoma Progression
    • Authors: Wang, R., Song, S., Qin, J., …, Ajani, J.A., Wang, L.
    • Year: 2023
    • Citations: 14
  • Epithelial SOX9 Drives Progression and Metastases of Gastric Adenocarcinoma by Promoting Immunosuppressive Tumour Microenvironment
    • Authors: Fan, Y., Li, Y., Yao, X., …, Ajani, J.A., Song, S.
    • Year: 2023
    • Citations: 24
  • A New Intronic Quantitative PCR Method Led to the Discovery of Transformation from Human Ascites to Murine Malignancy in a Mouse Model
    • Authors: Jin, J., Huo, L., Fan, Y., …, Song, S., Ajani, J.A.
    • Year: 2023
    • Citations: 1
  • Nivolumab Combination Therapy as First-Line Treatments for Unresectable, Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    • Authors: Rogers, J.E., Yamashita, K., Sewastjanow-Silva, M., …, Waters, R., Ajani, J.A.
    • Year: 2023
    • Citations: 1
  • GRK3 Is a Poor Prognosticator and Serves as a Therapeutic Target in Advanced Gastric Adenocarcinoma
    • Authors: Li, Y., Fan, Y., Xu, J., …, Song, S., Ajani, J.A.
    • Year: 2022
    • Citations: 3
  • Current Immune Checkpoint Inhibitor Genetic Biomarker Exploration in Gastrointestinal Tumors
    • Authors: Rogers, J.E., Yamashita, K., Sewastjanow Silva, M., Ajani, J.A.
    • Year: 2022